Effectiveness of Cannabidiol vs. Narcotics for Post Operative Pain Control in Elective Shoulder Arthroscopic Surgery

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05240755

Acronym

CBDS

Enrollment

Registered

2022-02-15

Start date

2022-07-01

Completion date

2024-08-20

Last updated

2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-operative Pain

Brief summary

This study is a prospective, randomized, nonblinded trial to evaluate the effectiveness of Cannabidiol (CBD) oil on post-operative pain control compared to opioid medications.

Interventions

DRUGCannabidiol Oil

Subjects will self-administer CBD sublingually.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age 18 years or older * Requiring shoulder arthroscopic surgery for soft tissue pathology * Able to complete surveys and follow-up visits

Exclusion criteria

* Younger than 18 years of age * Shoulder dislocation, fracture, previous surgery, coexisting extremity pathology, pregnancy.

Design outcomes

Primary

Measure	Time frame	Description
Post-operative pain	30 days post-operatively	Numerical Pain Scale (NRS): 0 being no pain, 10 being the worst pain imaginable. Higher scores are worse outcomes.

Secondary

Measure	Time frame	Description
Sleep Quality	30 days preoperatively leading up to surgery then 30 days postoperatively as well. Outcomes will be collected from surgery to 6 weeks postoperatively.	Insomnia Severity Index

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026